Higher Expression of Glucocorticoid Receptor in Peripheral Mononuclear Cells in Inflammatory Bowel Disease

Schottelius, Arndt; Wedel, Susanne; Weltrich, Renita; Rohde, Wolfgang; Buttgereit, Frank; Schreiber, Stefan; Lochs, Herbert
August 2000
American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p1994
Academic Journal
OBJECTIVE: Glucocorticoids are widely used in the treatment of inflammatory bowel disease (IBD). Up- and down-regulated expression of glucocorticoid receptors (GR) has been reported for different chronic inflammatory diseases. The aim of this study was to investigate the expression of GR and their apparent dissociation constant (Kd) in patients with IBD. METHODS: Thirty-nine patients with IBD (22 with ulcerative colitis, 17 with Crohn's disease) and 35 normal controls were studied. Twenty-five patients did not receive steroids. 14 patients were treated with steroids. Peripheral blood mononuclear cells from patients and controls were isolated using the Ficoll-Hypaque gradient and a whole cell [³HJ-dexamethasone binding assay and Scatchard plot analysis were performed to assess GR number and the apparent dissociation constant. Results were expressed as mean ± standard deviation. RESULTS: Normal controls showed an expression of 3969 ± 1555 GR per cell with an apparent dissociation constant of 6.16 ± 3.8 nmol/L. IBD patients without steroids had a significant increase both in the expression of GR per cell (6401 ± 2344; p < 0.0001; Wilcoxon-Mann-Whitney test) and in the apparent dissociation constant (11.02 ± 7.57 nmol/L; p = 0.006). Expression of GR in IBD patients was suppressed to normal levels under steroid treatment (4594 ± 2231: p = 0.024), hut Kd remained elevated (13.56 ± 9.05 nmol/L). Plasma cortisol levels were not different between IBD patients and the control group. CONCLUSIONS: Our data show a systemic increase in GR expression and a decrease in the affinity to the GR in IBD, in contrast to other inflammatory diseases such as rheumatoid arthritis and asthma. These changes point towards a systemic character of IBD, which might be considered in a decision between topical and systemic treatment.


Related Articles

  • BECLOMETHASONE DIPROPIONATE ADMINISTRATION VIA CECOSTOMY IN ULCERATIVE COLITIS. Matake, Hiroaki; Matsui, Toshiyuki; Yao, Tsuneyoshi; Sakurai, Toshihiro; Hirai, Fumihito; Nagae, Takashi; Takaki, Yasuhiro; Arima, Sumitaka; Imamura, Tatsuya // American Journal of Gastroenterology;Aug1997, Vol. 92 Issue 8, p1384 

    Beclomethasone dipropionate was administered via a cecostomy to four patients with active ulcerative colitis that was refractory to conventional glucocorticosteroid therapy. From a tube cecostomy, beclomethasone dipropionate solution was administered continuously throughout the day. Clinical...

  • sulfasalazine.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1091 

    The article presents information on sulfasalazine, an antirheumatic, gastrointestinal anti-inflammatory agent. It is used in the management of inflammatory bowel diseases such as ulcerative colitis, proctitis and proctosigmoiditis. The drug can also be used in the treatment of rheumatoid...

  • INFLAMMATORY BOWEL DISEASE.  // American Journal of Gastroenterology;Sep2007 Supplement 2, Vol. 102, pS458 

    The article presents abstracts on inflammatory bowel diseases which include an analysis on the therapeutic use of mesalamine-beclomethasone combination, a study on the efficacy of azathioprine in ulcerative colitis and a therapy on ulcerative colitis.

  • Tolerance of Nonsteroidal Antiinflammatory Drugs in Patients With Inflammatory Bowel Disease. Bonner, Gregory F.; Walczak, Michelle; Kitchen, Laurel; Bayona, Manuel // American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p1946 

    OBJECTIVE: We sought to examine whether use of nonsteroidal antiinflammatory drugs (NSAIDs) in an outpatient inflammatory bowel disease (IBD) population is associated with an increased likelihood of active disease. METHODS: We reviewed records of initial outpatient visits of IBD patients to the...

  • Effects of Nonsteroidal Antiinflammatory Drugs on Inflammatory Bowel Disease: A Case-Control Study. Felder, Joseph B.; Korelitz, Burton I.; Rajapakse, Ramona; Schwarz, Samuel; Horatagis, Angelo P.; Gleim, Gilbert // American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p1949 

    OBJECTIVE: The aim of this study was to determine whether a relationship exists between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and exacerbation or onset of inflammatory bowel disease (IBD). METHODS: Sixty consecutive IBD patients admitted to the hospital were carefully...

  • Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane reviews. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p24 

    The article presents a study that reviews the difference between various formulations of 5-aminosalicylic acid in patients with ulcerative colitis. It describes the method of the study that observes 2925 ulcerative colitis patients using randomized controlled trials. It outlines the findings of...

  • Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis. Atzeni, Fabiola; Ardizzone, Sandro; Bertani, Luca; Antivalle, Marco; Batticciotto, Alberto; Sarzi-Puttini, Piercarlo; Eliakim, Abraham R. // World Journal of Gastroenterology;5/28/2009, Vol. 15 Issue 20, p2469 

    Inflammatory bowel diseases (IBDs), particularly Crohn's disease (CD) and ulcerative colitis (UC), are associated with a variety of extra-intestinal manifestations (EIMs). About 36% of IBD patients have at least one EIM, which most frequently affect the joints, skin, eyes and the biliary tract....

  • Gut reaction. Karatzas, Irene // Alive: Canada's Natural Health & Wellness Magazine;Mar2008, Issue 305, p112 

    The article reports on the health benefits offered by probiotics in managing inflammatory bowel diseases. According to the author, probiotics have a beneficial effect on inflammatory bowel diseases since they restore a healthy bacterial balance that supports the digestion process and reduces...

  • Rheumatic Manifestations Associated with Inflammatory Bowel Diseases. Podswiadek, Marta; D'Incà, Renata; Sturniolo, Giacomo Carlo; Oliviero, Francesca; Punzi, Leonardo // Current Rheumatology Reviews;2007, Vol. 3 Issue 1, p47 

    Rheumatic manifestations, in particular joint complaints, are frequent features in inflammatory bowel disease (IBD), with a prevalence varying from 10 to 35%. Their spectrum is almost wide, involving bone, tendons, entheses and joints. Joint manifestations may be seen as arthralgia and/or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics